Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 22, 2015, Pages 2457-2463

  Böhm, Steffen ^a,b   Faruqi, Asma ^a   Said, Ian ^a   Lockley, Michelle ^a,b   Brockbank, Elly ^a   Jeyarajah, Arjun ^a   Fitzpatrick, Amanda ^a   Ennis, Darren ^b   Dowe, Thomas ^b   Santos, Jennifer L ^c   Cook, Linda S ^e   Tinker, Anna V ^c   Le, Nhu D ^c   Gilks, C Blake ^d   Singh, Naveena ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHEMOTHERAPY RESPONSE SCORE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOLOGIST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; TUBO OVARIAN HIGH GRADE SEROUS CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; HYSTERECTOMY; KAPLAN MEIER METHOD; MIDDLE AGED; OMENTUM; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SALPINGECTOMY; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; CYTOREDUCTION SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OMENTUM; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SALPINGECTOMY; TREATMENT OUTCOME;

EID: 84940539265     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.5212     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11. Lyon, France: International Agency for Research on Cancer, 2013 http://globocan.iarc.fr
2. Singh N, Gilks CB, Wilkinson N, et al: Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: A proposal. Histopathology 65:149-154, 2014
3. Vaughan S, Coward JI, Bast RC Jr, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11:719-725, 2011
4. du Bois A, Reuss A, Pujade-Lauraine E, et al: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials - By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234-1244, 2009
5. Goff BA: Advanced ovarian cancer: What should be the standard of care? J Gynecol Oncol 24:83-91, 2013
6. Vergote I, Tropé CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
7. Kehoe S, Hook J, Nankivell M, et al: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet [epub ahead of print on May 19, 2015]
8. Morrison J, Haldar K, Kehoe S, et al: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 8:CD005343, 2012
9. Thigpen T, duBois A, McAlpine J, et al: First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 21:756-762, 2011
10. Sassen S, Schmalfeldt B, Avril N, et al: Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38:926-934, 2007
11. Le T, Williams K, Senterman M, et al: Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 14:2649-2653, 2007
12. Muraji M, Sudo T, Iwasaki S, et al: Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol 131:531-534, 2013
13. Petrillo M, Zannoni GF, Tortorella L, et al: Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 211:632.e1-638.e1, 2014
14. National Institute for Health and Care Excellence: Ovarian cancer: The recognition and initial management of ovarian cancer. NICE guideline [CG122], 2011 https://www.nice.org.uk/guidance/cg122
15. BC Cancer Agency: Cancer Management Guidelines: Gynecology - Ovary-Epithelial Carcinoma, 2014 http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/gynecology/ovary-epithelial-carcinoma
16. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23, 1997
17. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations. Cancer 73:2680-2686, 1994
18. Chetty R, Gill P, Govender D, et al: International study group on rectal cancer regression grading: Interobserver variability with commonly used regression grading systems. Hum Pathol 43:1917-1923, 2012
19. Rustin GJ, Vergote I, Eisenhauer E, et al: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419-423, 2011
20. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, John Wiley & Sons, 2002
21. Agresti A: Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2007
22. Hynninen J, Lavonius M, Oksa S, et al: Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol 128:229-232, 2013
23. Ledermann JA, Raja FA, Fotopoulou C, et al: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi24-vi32, 2013
24. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3, 2014 http://www.nccn.org
25. Saha A, Varughese M, Gallagher CJ, et al: Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. Int J Gynecol Cancer 22:566-572, 2012
26. Pelissier A, Bonneau C, Chéreau E, et al: CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 135:542-546, 2014
27. Tan DS, Agarwal R, Kaye SB: Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7:925-934, 2006
28. Leinster DA, Kulbe H, Everitt G, et al: The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol 227:136-145, 2012
29. Genetic Pathology Evaluation Centre: Chemotherapy Response Score (CRS): Training Web site for CRS system. http://www.gpecimage.ubc.ca/aperio/images/crs
30. International Collaboration on Cancer Reporting: Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting Guide, Version 1.0. http://www.rcpa.edu.au/getattachment/1829b6fd-64c7-41cb-8d34-a606856b6ac5/ICCR-Ovary-FT-PPS-hyperlinked-guide.aspx
31. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
32. Tothill RW, Tinker AV, George J, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198-5208, 2008
33. Konstantinopoulos PA, Spentzos D, Karlan BY, et al: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555-3561, 2010
34. Gourley C, McCavigan A, Perren T, et al: Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 32, 2014 (suppl 5s; abstr 5502)
35. Riester M, Wei W, Waldron L, et al: Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst 106, 2014
36. Clarke B, Tinker AV, Lee CH, et al: Intraepithelial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22:393-402, 2009